A Potent and Selective Quinolone-Based PTPN22 Inhibitor with Improved Immunotherapeutic Activity
by promoting robust antitumor immunity, thus offering a promising lead molecule for the development of novel anticancer agents targeting PTPN22.
Authors
- Z Zhang (ORCID: https://orcid.org/0000-0001-5527-7910)
- W Li
- Benjamin Ayodipupo Babalola (ORCID: https://orcid.org/0000-0001-8188-9056)
- Brenson A. Jassim
- Jingmei Yu (ORCID: https://orcid.org/0009-0001-1826-6902)
- Haoran Zhang
- Zihan Qu
- Jianping Lin
- Frederick Nguele Meke
- Yunpeng Bai
- Jiajun Dong
Institutions
- Purdue University West Lafayette (US)
- Tarpo (Czechia) (CZ)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-07-02
- DOI
- https://doi.org/10.1021/acs.jmedchem.5c03467
- Primary Topic
- Protein Tyrosine Phosphatases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Purdue University
- National Cancer Institute